449 related articles for article (PubMed ID: 27365369)
1. Treatment pathways in an inception lupus cohort over the first three years.
Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
[TBL] [Abstract][Full Text] [Related]
2. Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus.
Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):822-828. PubMed ID: 30055090
[TBL] [Abstract][Full Text] [Related]
3. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
[TBL] [Abstract][Full Text] [Related]
4. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.
Urowitz MB; Gladman DD; Ibañez D; Fortin PR; Bae SC; Gordon C; Clarke A; Bernatsky S; Hanly JG; Isenberg D; Rahman A; Sanchez-Guerrero J; Wallace DJ; Ginzler E; Alarcón GS; Merrill JT; Bruce IN; Sturfelt G; Nived O; Steinsson K; Khamashta M; Petri M; Manzi S; Ramsey-Goldman R; Dooley MA; van Vollenhoven RF; Ramos M; Stoll T; Zoma A; Kalunian K; Aranow C
Arthritis Care Res (Hoboken); 2012 Jan; 64(1):132-7. PubMed ID: 21954226
[TBL] [Abstract][Full Text] [Related]
5. Disease evolution in late-onset and early-onset systemic lupus erythematosus.
Aljohani R; Gladman DD; Su J; Urowitz MB
Lupus; 2017 Oct; 26(11):1190-1196. PubMed ID: 28420066
[TBL] [Abstract][Full Text] [Related]
6. Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark.
Nørgaard JC; Stengaard-Pedersen K; Nørgaard M; de Thurah A
Lupus; 2015 Mar; 24(3):299-306. PubMed ID: 25318969
[TBL] [Abstract][Full Text] [Related]
7. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
8. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.
Ribi C; Trendelenburg M; Gayet-Ageron A; Cohen C; Dayer E; Eisenberger U; Hauser T; Hunziker T; Leimgruber A; Lindner G; Koenig K; Otto P; Spertini F; Stoll T; Von Kempis J; Chizzolini C;
Swiss Med Wkly; 2014; 144():w13990. PubMed ID: 25115978
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus.
Kwon HH; Bang SY; Won S; Park Y; Yi JH; Joo YB; Lee HS; Bae SC
Lupus; 2018 Sep; 27(10):1644-1651. PubMed ID: 29950160
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
11. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort.
Ugarte-Gil MF; Wojdyla D; Pastor-Asurza CA; Gamboa-Cárdenas RV; Acevedo-Vásquez EM; Catoggio LJ; García MA; Bonfá E; Sato EI; Massardo L; Pascual-Ramos V; Barile LA; Reyes-Llerena G; Iglesias-Gamarra A; Molina-Restrepo JF; Chacón-Díaz R; Alarcón GS; Pons-Estel BA
Lupus; 2018 Apr; 27(4):536-544. PubMed ID: 28857715
[TBL] [Abstract][Full Text] [Related]
13. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
Joo YB; Bae SC
Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
[TBL] [Abstract][Full Text] [Related]
14. Impact of telemedicine on disease activity assessment: A case-crossover study nested within a cohort of patients with systemic lupus erythematosus.
Almaghlouth I; Almalag HM; Alzuhair H; Alsaigh R; Bedaiwi A; Hassen LM; Alzomia S; Alanazi B; Alabdulkareem AM; Alahmari S; Asfina KN; Khalil N; Omair MA; Bedaiwi M
Lupus; 2023 Dec; 32(14):1610-1618. PubMed ID: 37921574
[TBL] [Abstract][Full Text] [Related]
15. Prolonged clinical remission in patients with systemic lupus erythematosus.
Steiman AJ; Urowitz MB; Ibañez D; Papneja A; Gladman DD
J Rheumatol; 2014 Sep; 41(9):1808-16. PubMed ID: 25086082
[TBL] [Abstract][Full Text] [Related]
16. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
[TBL] [Abstract][Full Text] [Related]
17. Serum uric acid is associated with damage in patients with systemic lupus erythematosus.
Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cardenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Cucho-Venegas JM; Alfaro-Lozano J; Rodriguez-Bellido Z; Pastor-Asurza CA; Perich-Campos RA; Alarcón GS; Ugarte-Gil MF
Lupus Sci Med; 2020; 7(1):e000366. PubMed ID: 32153795
[TBL] [Abstract][Full Text] [Related]
18. Prolonged remission in systemic lupus erythematosus.
Urowitz MB; Feletar M; Bruce IN; Ibañez D; Gladman DD
J Rheumatol; 2005 Aug; 32(8):1467-72. PubMed ID: 16078321
[TBL] [Abstract][Full Text] [Related]
19. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
20. Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
Lewandowski LB; Schanberg LE; Thielman N; Phuti A; Kalla AA; Okpechi I; Nourse P; Gajjar P; Faller G; Ambaram P; Reuter H; Spittal G; Scott C
Lupus; 2017 Feb; 26(2):186-194. PubMed ID: 27488473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
